Lilly’s obesity drug shows promise | Hydrogel for slowing tumor recurrence

Lilly shows great results with obesity drug

INDIANAPOLIS, IN—Eli Lilly has announced that its experimental drug for obesity helped patients lose up to 22.5% of body weight in a large clinical trial. The drug, tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster.

CX innovation in Madison

MADISON, WI—Medical device company Propeller Health offers a mobile platform for supporting respiratory health management. In this article, Forbes cites the company for its CX innovation in sensors that attach to patients’ existing inhalers that deliver insights on symptoms, triggers, and environmental factors to their phones.

Vanderbilt partners with AAMC

NASHVILLE, TN—The Association of American Medical Colleges has launched a pilot project with Vanderbilt University Medical Center to develop a cloud-based tool to inventory community-based activities to address health inequities. The medical center will work with statewide advocacy groups, public health departments and community-based organizations to develop the new tool over the first six months of the pilot.

Drug-releasing hydrogel can prevent tumor recurrence

MADISON, WI—Researchers from the University of Wisconsin-Madison have developed a drug-releasing hydrogel that can be applied post-surgery to prevent or slow tumor recurrence. They found that the gel could reduce biomarkers of cancer recurrence in mice, specifically those with colon cancer, melanoma, and triple-negative breast cancer. Next up are clinical trials that translate to humans.

More precise cancer diagnosis and treatment with AI

ROCHESTER, MN–The Mayo Clinic is partnering with South Korean AI company Vuno to develop AI and machine learning for more precise diagnosis and treatment stratification in cancer. The collaborative agreement will combine Mayo Clinic’s AI research, clinical expertise and resources with Vuno’s AI research and development capabilities to create a broad spectrum of predictive and prognostic biomarkers.